JTO Clinical and Research Reports · 2021 · 11 citations · 13 references
MedicineGeriatric MedicineOncologyChemotherapyPalliative MedicinePalliative OncologyConcurrent ChemoradiationGeriatric Cancer AssessmentGeriatric OncologyToxicity ManagementAdjuvant Concurrent ChemoradiationConcurrent Chemoradiation TherapyConcurrent Chemoradiotherapy ToxicityDurvalumab Consolidation TherapyDurvalumab TherapyGeriatric Chemotherapy ToxicityOncologic Outcomes Assessment
INTRODUCTION: The addition of durvalumab after chemoradiation therapy (CRT) in unresectable stage III NSCLC significantly improves survival. The benefit of this approach in elderly patients is controversial given the toxicity associated with CRT and, thus, may be underutilized. We sought to investigate the outcomes of elderly patients treated with CRT without or without durvalumab at our center. METHODS: We reviewed all stage III patients with NSCLC treated with CRT between 2018 and 2020. Patients were analyzed on the basis of age: less than 70 years and 70 years and older. The end points evaluated were treatment patterns, toxicity, progression-free survival, and overall survival. RESULTS: = 0.98). CONCLUSIONS: Well-selected elderly patients can be treated safely with CRT followed by durvalumab with similar survival benefits compared with their younger counterparts. We would advocate for the referral of all elderly patients for oncologic assessment to avoid undertreatment.
13
Hude Quan, Bing Li, Chantal Marie Couris et al. · American Journal of Epidemiology · 2011 · 5.9K citations · Full text
Health Professions, Health Services Administration, Clinical Classification Systems +16
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Shinji Atagi, Masaaki Kawahara, Akira Yokoyama et al. · The Lancet Oncology · 2012 · 238 citations
Thomas E. Stinchcombe, Ying Zhang, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 86 citations · Full text